Heparin-induced thrombocytopenia and other immune thrombocytopenias: Lessons from mouse models

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 5, 2004, Pages 559-568

  McKenzie, Steven E ^a,b   Reilly, Michael P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Dept of Medicine and Pediatrics ^*  (United States)

Author keywords

Antiplatelet antibodies; Heparin induced thrombocytopenia thrombosis; HITT; Immune thrombocytopenia; ITP; Mouse models

Indexed keywords

FC RECEPTOR; HEPARIN; IMMUNOGLOBULIN; THROMBOCYTE FACTOR 4;

ANIMAL MODEL; EPITOPE MAPPING; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MODELS, BIOLOGICAL; THROMBOCYTOPENIA;

EID: 7044250868     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835676     Document Type: Review

References (33)

1. McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol 2003;25(suppl 1):S57-S61
2. Beardsley DS. Pathophysiology of immune thrombocytopenic purpura. Blood Rev 2002;16:13-14
3. Beardsley DS. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci 1998;19:237-244
4. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239-248
5. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
6. Vesley SK, Buchanan GR, Adix L, et al. Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology. J Pediatr Hematol Oncol 2003;25:130-133
7. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390-398
8. Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 2002;95:1209-1212
9. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100
10. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229-1236
11. Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 2003;101:621-623
12. Riksen NP, Keuning JJ, Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med 2003;61:262-265
13. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-1346
14. Schwartz J, Bussel JB. Anti-CD40L: biology and therapy in ITP. Blood 2004;103:1178-1179
15. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-730
16. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887-895
17. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96
18. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251
19. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239
20. Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpuraprone (NZW × BXSB)F1 mice. Blood 1993;82:837-844
21. McKenzie SE, Schreiber AD. Biological advances and clinical applications of Fc receptors for IgG. Curr Opin Hematol 1994;1:45-52
22. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV, Organization of the human and mouse low-affinity FcγR genes. Science 1990;248:732-735
23. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor/FcγRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999;162:4311-4318
24. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995;3:21-26
25. Samuelsson A, Towers T, Ravetch J. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486
26. Crow AR, Song S, Semple J, Freedman J, Lazarus A. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001;115:679-686
27. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002;100:2087-2093
28. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 2000;95:1533-1540
29. Reilly MP, Taylor SM, Hartman NK, Arepally G, Cines DB, Poncz M. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA. Blood 2001;98:2442-2447
30. Rauova L, Poncz M, McKenzie SE, et al. High molecular weight complexes of heparin and PF4 are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2003;102:126A
31. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001;98:1252-1254
32. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302
33. George J, Mulkins M, Casey S, Schatzman R, Sigal E, Harats D. The effects of N-6 polyunsaturated fatty acid supplementation on the lipid composition and atherogenesis in mouse models of atherosclerosis. Atherosclerosis 2000;150:285-293